Document:

EX-10.1

 EXECUTION VERSION 

Exhibit 10.1 
 RETIREMENT
AGREEMENT 
 This RETIREMENT AGREEMENT (the “Agreement”) is entered into this 23rd day of August, 2017 by and between
BioDelivery Sciences International, Inc., (the “Company”), and Mark A. Sirgo (“Sirgo”). Sirgo and the Company may be collectively referred to as the “parties” or individually referred to as a
“party.” 
 WHEREAS, Sirgo has heretofore served in various senior executive positions with the Company since August 24, 2004
and presently serves as the Company’s President and Chief Executive Officer; 
 WHEREAS, Sirgo has elected to voluntarily retire from
the position of President and Chief Executive Officer of the Company to allow for a period of transition during which the Company will search for a new President and/or Chief Executive Officer; 

WHEREAS, in connection with Sirgo’s retirement, the Company desires to provide Sirgo with certain benefits; and 

WHEREAS, the parties intend that this Agreement will set out the terms of Sirgo’s retirement from the Company. 

NOW, THEREFORE, in consideration of the promises and the mutual covenants herein contained, and for other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows. 
 1. Retirement from the Company; Mutual
Termination of Employment Agreement. 
 (a) Sirgo will remain employed by the Company as President and Chief Executive Officer during a
period of time (the “Transition Period”) in order to provide for an orderly transition of his duties. The Transition Period will commence as of the date Sirgo signs this Agreement (the “Signature Date”) and will
continue until January 2, 2018 (the “Retirement Date”). Sirgo’s employment with the Company and each of its subsidiaries will terminate as of the Retirement Date. Sirgo shall be paid his full compensation and participate
in full benefits through the Retirement Date at the same levels he receives such compensation and participates in such benefits at the Signature Date; provided, however, that such compensation shall include the increase in base salary that
was approved by the Board in January 2017, but temporarily deferred for the senior management team at the request of Sirgo, retroactive to January 1, 2017; provided further that any catch-up in payments of base salary to implement the
increase shall be made on or before December 31, 2017. Sirgo hereby resigns from the positions of President and Chief Executive Officer of the Company and each of its subsidiaries by reason of his voluntary retirement effective as of the
Retirement Date. Sirgo acknowledges that, as of the Signature Date, he is entering into this Agreement of his own choosing and is not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies
(including accounting or financial policies) or practices. Notwithstanding anything else in this Agreement to the contrary, the Board may remove Sirgo from the position of Chief Executive Officer and President prior to the January 2, 2018 only
for “Good Cause” (as defined herein), but in such case, Sirgo shall remain an employee through the Retirement Date (and put on paid administrative leave, at the Board’s discretion), shall be entitled to full pay and benefits through
the Retirement Date, and shall be entitled to the payments and benefits set forth in this Agreement, including but not limited to those specified in Section 2. As used in this Agreement, the term “Good Cause” shall mean:
(i) an act or omission constituting gross misconduct or willful misfeasance by Sirgo; (ii) the commission by Sirgo of an act of fraud, 

 EXECUTION VERSION 

 

 
embezzlement or any felony or crime of dishonesty in connection with his Company duties; or (iii) conviction of Sirgo of a felony or any other crime that would materially and adversely
affect (A) the business reputation of the Company or (B) the performance of Sirgo’s Company duties. 
 (b) It is expressly
agreed that Sirgo also presently serves as a director on, and as Vice Chairman of, the Company’s Board of Directors (the “Board”), and that this Agreement does not represent a retirement or resignation by Sirgo from his
position as a director or as Vice Chairman. It is further agreed that, up until and following the Retirement Date, Sirgo shall continue to serve as Vice Chairman of the Board, subject to the provisions of applicable law, the Company’s
Certificate of Incorporation, as amended, and the Company’s Amended and Restated Bylaws. Sirgo shall serve as Vice Chairman of the Board and a director of the Company until the earlier of his death, resignation, removal by the Company’s
stockholders, voluntary refusal to stand for reelection as a director or the decision of the Board to not nominate him for reelection as a director when his current term is concluded in 2019. For his service on the Board, Sirgo shall be entitled to
receive annual cash and equity award payments as determined by the Compensation Committee of the Board. 
 (c) Following the Retirement
Date, Sirgo shall be permitted to consult with, be employed by, act as a director for, or otherwise be associated with, any other business, subject in all instances to the terms of this Agreement, the surviving terms of the Employment Agreement (as
defined below) (including the non-competition provisions thereof) and the Confidentiality Agreement (as defined below), as modified in Section 1(f) of this Agreement.. 

(d) Except as set forth in this Agreement, as provided by the specific terms of a Company benefit plan or as required by law, as of the
Retirement Date, all of Sirgo’s benefits as an officer and employee of the Company will be terminated; provided, however, that Sirgo will be entitled to any and all vested rights as of the Retirement Date in any benefits, and to payment
of his accrued but unused vacation in his last paycheck. 
 (e) By its execution of this Agreement, the Company acknowledges and agrees that
Sirgo’s retirement shall be a “Retirement” (including a retirement “in good standing”) as defined in and for purposes of the Company’s 2011 Equity Incentive Plan, as amended (the “Plan”). 

(f) By their mutual execution of this Agreement, the Company and Sirgo hereby voluntarily agree to terminate Sirgo’s employment agreement
with the Company, dated August 24, 2004, as amended by that First Amendment thereto (collectively the “Employment Agreement”) as of the Retirement Date; provided, however, that: (i) the terms and conditions of the
Employment Agreement relating to termination, including but not limited to the provisions of Section 4 in the Employment Agreement, are terminated as of the Signature Date and will be of no force or effect and replaced by the terms of this
Agreement; and (ii) the terms and conditions of the Employment Agreement relating to confidentiality, non-competition, and other terms of the Employment Agreement which expressly survive termination, shall so survive and are incorporated herein
by reference; provided further that the Company and Sirgo agree to and hereby do amend the Employment Agreement as follows: (aa) the post-termination restrictive period set forth in Section 11 of the Employment Agreement shall not extend
beyond one (1) year following the Retirement Date; (bb) Section 11(a)(i)(A) shall be deleted; (ccc) Section 11(a)(i)(B) shall be deleted and replaced with the following: “use of buccal delivery or injectable micropartical
technology for the delivery of drugs that directly compete with the drugs or products offered by the Company at the time of Employee’s termination of employment”; and (ddd) the last sentence of the last paragraph of Section 11
(following 11(d)) shall be deleted and replaced with the following: “Nothing in this Agreement shall preclude Employee from employment at a non-for-profit or governmental institution, provided that no for-profit business involved in a
Competitive Activity as defined in Section 11(a) shall derive a benefit from Employee’s employment.” 

  
 2 

 EXECUTION VERSION 

 

 (g) In addition, by their mutual execution of this Agreement, the Company and Sirgo agree
that the terms and conditions of that certain Confidentiality and Intellectual Property Agreement, dated August 24, 2004 by Sirgo in favor of the Company (the “Confidentiality Agreement”) shall not terminate and shall remain in
full force and effect following the Retirement Date and are incorporated herein by reference; provided, however, that the Company and Sirgo agree to and hereby do amend the Confidentiality Agreement as follows: (i) the post-termination
restrictive period set forth in Section 10 of the Confidentiality Agreement shall not extend beyond two (2) years following the Retirement Date; and (ii) the last sentence of Section 10 shall be deleted in its entirety and
replaced with the following: “Employee further agrees that, for a period of two (2) years following the expiration or termination of the Employment Agreement, should Employee be approached by a person who Employee has actual knowledge is,
or was within the previous three (3) months, an employee of the Company or any subsidiary or joint venture thereof, Employee will not (directly or indirectly) offer to nor employ or retain any such person as an employee, independent contractor
or agent; provided, however, this provision shall not apply to any person whose employment was terminated by the Company.” 
 (h) Sirgo
further agrees that if, at any time during his membership on the Board, regardless of the foregoing Confidentiality Agreement has terminated or expired, he engages in conduct that Section 11 of the Confidentiality Agreement prohibits, Sirgo
will immediately resign from his position as a Director of the Board and as Vice Chairman of the Board. 
 2. Retirement Benefits. In
consideration for entering into and not revoking the Supplemental Release Agreement referred to in Section 5(c) below, the Company will provide Sirgo with the following retirement payments and benefits: 

(a) Retirement Payment. Subject to the occurrence of the Effective Date (as defined in the Supplemental Release Agreement) (the
“Effective Date”) and to Sirgo’s compliance with the terms of this Agreement and the Supplemental Release Agreement (with respect to payments under Section 2(a)(ii), (iii) and (iv)), the Company will pay Sirgo the
following amounts: (i) a cash payment equal to $787,000.00 (less applicable withholdings) (the “Signing Payment”) to be paid in lump sum within ten (10) days of the Signature Date, (ii) a cash payment equal to
$787,000.00 (less applicable withholdings) (the “Retirement Payment”) to be paid in lump sum on January 15, 2018; (iii) if the Retirement Date occurs after there has been a Change in Control (as defined in
Section 4(e) of the Employment Agreement, as amended), an additional cash payment equal to $236,000 (less applicable withholdings) (the “CIC Retirement Payment”) to be paid in lump sum within ten (10) days of the
Retirement Date, and (iv) if a Change in Control occurs on or after the Retirement Date and within twelve (12) months following the Retirement Date, with a company with whom Sirgo had contact about a potential transaction in his capacity
as an employee of the Company (“Contact About a Potential Transaction” as defined below) prior to the Retirement Date, then the Company shall pay to Sirgo an additional amount equal to $236,000 (less applicable withholdings) (the
“Additional Retirement Payment”) in lump sum on the closing of the Change in Control. For purposes of this Section 2(a), “Contact About a Potential Transaction” shall include, among other things, Sirgo, or employees
for whom Sirgo supervised or had responsibility, having discussed with, contacted to discuss, in both cases whether informal or formal, or having identified a company, entity or person as a potential party to a transaction that contemplated a
potential Change in Control. 
 (b) Reimbursement for Costs of Continued Health Benefits. The Company shall reimburse Sirgo for the
actual additional costs of continuation of Sirgo’s group health and dental insurance under the Consolidated Omnibus Reconciliation Act of 1985 (“COBRA”), at the same level in which he participated as of the Retirement Date, for
the eighteen (18) month period following the Retirement Date, provided that Sirgo shall bear full responsibility for applying for COBRA coverage, and 

  
 3 

 EXECUTION VERSION 

 

 
nothing herein shall constitute a guarantee of COBRA continuation coverage or benefits or a guarantee of eligibility for health benefits. Notice of COBRA continuation benefits shall be provided
under separate cover. Reimbursements under this Section 2(b) shall be made on a monthly basis beginning in the month after the Supplemental General Release Agreement, required under Section 9(b), becomes effective and non-revocable. Sirgo
shall not be entitled to a cash payment or other benefit in lieu of the reimbursements provided for herein or for amounts in excess of the actual costs of premiums for the coverages hereunder. 

(c) Equity Awards. Subject in each case to the occurrence of the Effective Date and to Sirgo’s compliance with the terms of this
Agreement and the Supplemental Release Agreement: 
  

	 	(i)	Existing Options. The Company acknowledges and agrees that all options (the “Options”) to purchase shares of Company common stock, par value $.001 per share (the “Common Stock”)
previously issued to Sirgo under the Plan or under any other Company plan or arrangement (including, without limitation, the Company’s Amended and Restated 2001 Incentive Plan, as amended) have vested. The Company further agrees that all such
vested Options shall not terminate on the 90th day following the Retirement Date, but shall, instead, remain outstanding for the remaining life of such Options; provided, however, that
Sirgo acknowledges and agrees that (A) any unexercised Options held following the 90th day following the Retirement Date shall lose their status as incentive stock options
(“ISOs”) within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended, (the “Code”) and shall revert to nonqualified stock options; and (B) he has been made aware of and understands
the ramifications to him of the change of status of his Options from ISOs to non-qualified options. 

  

	 	(ii)	2017 Equity Award. Sirgo will be entitled to receive his 2017 equity award bonus under and in accordance with the terms of the Employment Agreement and the Plan (the “2017 Equity Award”), with
the type and amount thereof to be determined in accordance with the Company’s prevailing compensation policies and procedures for Sirgo in his role as President and Chief Executive Officer of the Company relative to the 2017 equity awards made
to the Company’s other officers. The Company and Sirgo acknowledge and agree that such annual equity awards have in the past periods been awarded as vesting restricted stock units (“RSUs”) under the Plan, but in light of
Sirgo’s Retirement, the 2017 Equity Bonus will be awarded in the form of a one-time issuance of fully vested shares of Common Stock under the Plan, the number of which will be determined: 

(A) with respect to RSUs which by their terms would vest with the passage of time (“Time Vesting RSUs”), a
number of shares of Common Stock equal to (1) the Net Present Value (as defined below) of the Time Vesting RSUs that would have been issued to Sirgo for the 2017 Equity Award had he not retired divided by (2) the 30-day volume weighted
average price of the Common Stock (the “30-day VWAP”) as of the date of issuance of the 2017 Equity Bonus; and 

  
 4 

 EXECUTION VERSION 

 

 (B) with respect to RSUs which by their terms would vest based on future
performance (“Performance Vesting RSUs”), a number of shares of Common Stock determined by multiplying the number of Performance Vesting RSUs that would have been issued to Sirgo for the 2017 Equity Award had he not retired by 0.66.

  

	 	(iii)	LTIP Awards. Sirgo will continue to be entitled to receive (if applicable) one hundred percent (100%) of his regular award of vested Common Stock (the “LTIP Stock”) under the Company’s
Performance Long Term Incentive Plan (the “LTIP”), with the amount of such LTIP Stock to be determined and issued in accordance with the terms and provisions of the LTIP. The issuance of the LTIP Stock to Sirgo as provided for above
shall occur, if applicable, concurrently with the issuance of LTIP Stock to the Company’s officers, but no later than March 15, 2018. Should Sirgo (i) voluntarily resign from his officer positions with the Company prior to the
Retirement Date or (ii) voluntarily resign from the Board, in each case prior to payment of any amount of LTIP Stock as provided for herein, Sirgo’s right to receive LTIP Stock from and after that time shall terminate. Notwithstanding any
provisions of this Agreement, the Plan, or the LTIP to the contrary, in the event a Change in Control occurs on or within twelve (12) months following the Retirement Date with a company with whom Sirgo had Contact About a Potential Transaction
(as defined in Section 2(a) of this Agreement) prior to his Retirement Date, then the Company shall issue to Sirgo, as an additional retirement benefit, fully vested shares of the Company’s Common Stock in an amount equal to the number of
shares Sirgo would have received pursuant to the LTIP had he remained employed with the Company through the Change in Control. 

  

	 	(iv)	Previously Awarded RSUs. As of the Retirement Date, all previously granted Time Vesting RSUs issued to Sirgo pursuant to the Plan that are unvested as of the Retirement Date shall terminate and, in lieu thereof,
Sirgo shall receive a one-time issuance of fully vested shares of Common Stock under the Plan, the number of which will be determined with reference to the Time Vesting RSUs being terminated by dividing (A) the Net Present Value of such Time
Vesting RSUs by (B) the 30-day VWAP as of the Retirement Date. For the avoidance of doubt, such termination shall not apply to any Time Vesting RSUs which, by their terms, vest prior to the Retirement Date. In addition, as of the Retirement
Date, all previously granted RSUs issued to Sirgo pursuant to the Plan which vest due to achievement of future performance milestones that are unvested as of the Retirement Date shall terminate and, in lieu thereof, Sirgo shall receive a one-time
issuance of 250,000 fully vested shares of Common Stock under the Plan. 

  

	 	(v)	Net Issuance. Sirgo shall be entitled to the customary Company benefit allowing for the “net issuance” by the Company of Common Stock underlying the Options or RSUs or Common Stock comprising the LTIP
Stock in order to provide Sirgo the opportunity (on his own or through the Company) to sell shares of Common Stock, the proceeds of which will be utilized to pay Sirgo’s federal, state or local income or withholding tax liability.

  
 5 

 EXECUTION VERSION 

 

	 	(vi)	Definition of Net Present Value. As used in this Agreement, the term “Net Present Value” means the net present value of a subject RSU, calculated pursuant to the following formula:

  
 

 
 Where: 

NPV = Net Present Value of a subject RSU. 

i = 4.0%, the agreed upon annual interest rate for one compounding (i.e., vesting) period. 

N = the total number of vesting periods for the subject RSU. 

t = the compounding period (expressed in years) between the Retirement Date and the applicable vesting date(s) specified in the subject
RSU (i.e., either one, two or three vesting years or partial years, as the case may be). 
 R = (a) the number of shares of common
stock underlying the applicable RSU that would vest on the applicable vesting date(s) specified in the subject RSU (assuming full vesting on each such vesting date) multiplied by (b) the 30-day VWAP on the Retirement Date. 

 

	 	(c)	Health Benefits. Sirgo will continue to receive coverage under the Company’s medical, dental and FSA plans at his current elections and premium rates through the Retirement Date. After the Retirement Date,
the provisions of Section 2(b) shall apply with respect to reimbursement for continuation of Sirgo’s health benefits. All other benefits not expressly mentioned herein, including, but not limited to, disability and life insurance benefits,
will end on the Retirement Date. 

  

	 	(d)	Expense Reimbursement. Sirgo will receive payment for all approved and outstanding expense reports owed in connection with appropriate business expenses through the Retirement Date. All requests for
reimbursements shall be submitted no later than January 2, 2018, and reimbursements shall be provided within thirty (30) days, but in no event after February 1, 2018. 

 

	 	(e)	401(k). Sirgo will be entitled to any Company 401(k) benefits in accordance with the terms and conditions of the applicable Company plans (noting that any 401(k) deferrals and matching contributions will
terminate as of the Retirement Date in accordance with the terms and conditions of those plans). 

  

	 	(f)	 D&O Coverage. For a period of six (6) years after the Retirement Date, the Company or any
successor to the Company shall purchase and maintain, at its own expense, directors’ and officers’ liability insurance providing coverage to Sirgo on terms that are no less favorable than the coverage provided to other

  
 6 

 EXECUTION VERSION 

 

	 	
directors and similarly situated executives of the Company. In addition, Sirgo shall be entitled to indemnification from the Company, including advancement, to the fullest extent allowed by, and
subject to the provisions of, the Company’s Certificate of Incorporation, as amended, and Amended and Restated Bylaws. 

  

	 	(g)	Reimbursement of Attorneys’ Fees. The Company will reimburse Sirgo for his reasonable attorneys’ fees incurred in connection with the preparation and negotiation of this Agreement, up to a maximum of
$40,000. Such amount will be paid within thirty (30) days of Sirgo’s submission of acceptable documentation of such fees following the Signing Date, but in no event later than August 31, 2017. 

 

	 	(h)	Acknowledgement and Waiver. Sirgo acknowledges that the compensation and benefits available to him under this Agreement are in lieu of any compensation and benefits he would be eligible to receive under the
Employment Agreement upon the termination of his employment. Accordingly, except for the compensation and benefits provided for under this Agreement upon the termination of Sirgo’s employment, Sirgo hereby waives any severance, separation or
post-termination compensation available to him upon the termination of his employment as provided under the Employment Agreement. For the avoidance of doubt, however, this waiver does not include any right to the acceleration of vesting or other
benefits that may be available to Sirgo under any of the Company’s equity plans. For the further avoidance of doubt, the Company acknowledges and agrees that Sirgo is entitled to the compensation and benefits set forth in this Agreement,
including without limitation Section 2, upon the termination of his employment for any reason at any time. 

 3. Press
Releases. Sirgo and the Company shall cooperate in preparing and shall mutually agree upon a press release and all other public announcements concerning Sirgo’s retirement under this Agreement. 

4. Release of Claims. 

(a) Sirgo Release. In consideration of the mutual agreements and covenants herein contained, by signing this Agreement, Sirgo knowingly
and voluntarily releases and forever discharges the Company and its affiliates, subsidiaries, divisions, insurers, predecessors, successors and assigns, and their current and former employees, attorneys, officers, directors and agents thereof, both
individually and in their business capacities, and their employee benefit plans and programs and their administrators and fiduciaries (collectively referred to throughout the remainder of this Agreement as “Company Released
Parties”), of and from any and all claims, known and unknown, asserted or unasserted, which Sirgo has or may have against the Company or any Company Released Parties as of the date of execution of this Agreement, including, but not limited
to: (i) any claims, whether statutory, common law, or otherwise, arising out of the terms or conditions of his employment at the Company; (ii) any claims, whether statutory, common law, or otherwise, arising out of the facts and
circumstances of his employment and the termination of his employment at the Company; (iii) any claims for breach of contract, quantum meruit, unjust enrichment, breach of oral promise, tortuous interference with business relations, injurious
falsehood, defamation, negligent or intentional infliction of emotional distress, invasion of privacy, and any other common law contract and tort claims; (iv) any claims for unpaid or lost benefits or salary, bonus, vacation pay, severance pay,
or other compensation; (v) any claims for attorneys’ fees, costs, disbursements, or other expenses; (vi) any claims for damages or personal injury; (vii) any claims of employment discrimination, harassment or retaliation, whether
based on federal, state, or local law or 

  
 7 

 EXECUTION VERSION 

 

 
judicial or administrative decision; and (viii) any claims arising under the Fair Labor Standards Act, 29 U.S.C.§ 201, et seq.; Title VII of the Civil Rights Act of 1964, 42 U.S.C.
§ 2000e, et seq. (as amended); the Civil Rights Act of 1866, 42 U.S.C. § 1981; the Civil Rights Act of 1991, Pub. Law No. 102-166; the National Labor Relations Act, 29 U.S.C. § 151, et seq.; the Family and Medical Leave Act, 29
U.S.C. § 2601 et seq.; the Rehabilitation Act of 1973, 29 U.S.C. § 701, et seq.; the Age Discrimination in Employment Act; the Older Workers Benefit Protection Act; the Worker Adjustment and Retraining Notification Act; the Americans With
Disabilities Act, 42 U.S.C. § 12101, et seq.; the Employee Retirement Income Security Act of 1974, 29 U.S.C. §1001, et seq., the Sarbanes-Oxley Act of 2002, 18 U.S.C. §1514A, et seq., the Dodd-Frank Wall Street Reform and Consumer
Protection Act, claims under North Carolina or other state laws, including, but not limited to, the North Carolina Retaliatory Employment Discrimination Act, the North Carolina Persons with Disabilities Protection Act, the North Carolina Equal
Employment Practices Act, and/or any other federal, state or local statute, law, ordinance, regulation or order, or the common law, or any self-regulatory organization rule or regulation. The enumeration of specific rights, claims, and causes of
action being released should not be construed to limit the general scope of the foregoing release. It is the intent of Sirgo and the Company that by the foregoing release, Sirgo is giving up all rights, claims, and causes of actions against the
Company Released Parties which accrued prior to the effective date hereof, whether or not he is aware of them and whether or not any damage or injury has yet occurred. This release does not include either Party’s right to enforce the terms of
this Agreement. In connection with this release provision, Sirgo does not waive his right to file a charge or participate in any proceeding of any federal, state or local governmental agency, including the Equal Employment Opportunity Commission,
the National Labor Relations Board, and the Securities and Exchange Commission. To the extent permitted by law, Sirgo agrees that if such a claim is made, Sirgo shall not be entitled to recover any individual monetary relief or other individual
remedies should any administrative agency pursue any claim on his behalf. Nothing in this Agreement extinguishes any claims Sirgo may have: (i) against the Company for breach of this Agreement; (ii) against any of the Company Released
Parties for any claims arising from events that occur following the Effective Date; or (iii) related to the Company’s obligation, if any, to indemnify Sirgo as an officer of the Company, including under any directors’ and
officers’ liability policy maintained by the Company. 
 (b) Company Release. In consideration of the mutual agreements
and covenants herein contained, by signing this Agreement, the Company knowingly and voluntarily releases and forever discharges Sirgo, his affiliates, and his attorneys and representatives (collectively referred to throughout the remainder of this
Agreement as “Sirgo Released Parties”), of and from any and all claims, known and unknown, asserted or unasserted, which the Company has or may have against Sirgo or any Sirgo Released Parties as of the date of execution of this
Agreement, including, but not limited to, (i) any claims, whether statutory, common law, or otherwise; (ii) any claims for breach of contract, breach of fiduciary duty, conversion, quantum meruit, unjust enrichment, breach of oral promise,
tortuous interference with business relations, injurious falsehood, defamation, and any other common law contract and tort claims; (iii) any claims for attorneys’ fees, costs, disbursements, or other expenses; and (vi) any claims for
damages; provided, however, that expressly excluded from such released claims are (A) claims arising out of Sirgo’s capacity as an officer or employee of the Company for fraud, criminal acts, intentional misconduct or actively
concealed grossly negligent acts, and (B) any claims relating specifically to Sirgo’s actions or omissions as a director of the Company. The enumeration of specific rights, claims, and causes of action being released should not be
construed to limit the general scope of the foregoing release. It is the intent of Sirgo and the Company that by the foregoing release, the Company is giving up all rights, claims, and causes of actions against the Sirgo Released Parties which
accrued prior to the effective date hereof, whether or not he is aware of them and whether or not any damage or injury has yet occurred. This release does not include either Party’s right to enforce the terms of this Agreement. Nothing in this
Agreement extinguishes any claims the Company may have: (i) against Sirgo for breach of this Agreement or the Supplemental Release Agreement; or (ii) against any of the Sirgo Released Parties for any claims arising from events that occur
following the Effective Date. 

  
 8 

 EXECUTION VERSION 

 

 (c) Supplemental Release. Additionally, on the Retirement Date, or within there
(3) days thereafter, Sirgo and the Company agree to execute and deliver to the other party a Supplemental Release Agreement in the form attached as hereto as Exhibit “A” containing a general release of claims
co-extensive and substantially similar with the release set forth above to include a release of all claims through and including the Retirement Date (the “Supplemental Release Agreement”); provided, however, that the
Company’s failure to execute the Supplemental Release Agreement shall not relieve the Company of its full obligations under this Agreement, including but not limited to its obligations under Section 2. 

6. Affirmations. Sirgo hereby affirms, represents and warrants that: 

(a) he has not filed, caused to be filed, or presently is a party to any claim against any Released Party; 

(b) except for the payments and benefits provided for in this Agreement, he has been paid and/or has received all compensation, wages,
bonuses, commissions, and/or benefits to which Sirgo may be entitled; 
 (c) he has been granted and received any and all leaves (paid or
unpaid) to which he may have been entitled during his employment, including any leave to which he was entitled under the Family and Medical Leave Act or local leave or disability accommodation laws; 

(d) he has no known workplace injuries or occupational diseases; 

(e) he has not been retaliated against for reporting any allegations of wrongdoing by any Released Party, including any allegations of
corporate fraud; 
 (f) this Agreement states fully all agreements, understandings, promises, and commitments as between himself and the
Company relating to the termination of Sirgo’s employment; 
 (g) in deciding to sign this Agreement, he has not relied on any
representations, statements, agreements, understandings, promises, or commitments that are not expressly set forth in this Agreement; 
 (h)
he has reviewed this Agreement in its entirety; 
 (i) he has been afforded at least twenty-one (21) calendar days within which to
consider this Agreement and that he has, by this Agreement, been advised in writing to consult with legal counsel before signing this Agreement; 

(j) should he choose to sign this Agreement before the expiration of twenty-one (21) days, or choose not to consult legal counsel, he
does so freely and knowingly, and waives any and all claims that such action or inaction would affect the validity of this Agreement; and 

(k) any changes to this Agreement, whether material or immaterial, do not restart the twenty-one (21) day period. 

7. Confidentiality. Sirgo hereby ratifies and confirms the terms of the Confidentiality Agreement and further represents and agrees
that he will not (except as required by law) disclose information regarding the specific terms of this Agreement to anyone outside of the Company except his 

  
 9 

 EXECUTION VERSION 

 

 
immediate family, or his attorneys, accountants, or financial advisors as reasonably necessary. Notwithstanding the foregoing, nothing in this Agreement shall be construed to prohibit Sirgo from
reporting conduct to, providing truthful information to or participating in any investigation or proceeding conducted by any federal or state government agency or self-regulatory agency. 

8. Cooperation. By signing this Agreement, Sirgo agrees that, for a period of equal to the period of time under which Sirgo is
covered by the director and officer liability insurance (including tail coverage) of the Company or its successors (the “Cooperation Period”), he will, at the Company’s expense, cooperate fully with the Company and its
officers, directors, employees, agents, successors, assigns and legal counsel in connection with any claim, complaint, charge, suit or action previously or hereafter asserted or filed by or against the Company or any of the Released Parties of the
Company which relates to, arises out of or is connected directly or indirectly with (i) Sirgo’s service as an officer or director of the Company, or (ii) any other relationship or dealings between Sirgo and the Company or any of the
Company’s Released Parties. Further, during the Cooperation Period, Sirgo agrees that, in the event that he is subject to a valid and enforceable subpoena or court order that compels his testimony at a trial, hearing or deposition concerning
his relationship with the Company or any other matter relating to the Company or any of the Company’s Released Parties, he will inform the Chairman of the Board of the Company in writing within seventy two (72) hours of his becoming aware
that he is required to testify and will reasonably cooperate with the Company in minimizing any disclosure by Sirgo of any confidential or proprietary information of the Company. Sirgo expressly agrees that, to the extent permitted by applicable law
or court order, he will continue to cooperate with the Company in accordance with this Section after receiving said subpoena or court order. No part of this Agreement will abrogate Sirgo’s obligation to provide truthful testimony under oath.
The Company shall compensate Sirgo (following his provision of appropriate documentation) at an hourly rate of $350 for any time he is required to devote to his obligations under this Section 8, and shall reimburse Sirgo for all of his
reasonable out of pocket expenses; provided, however, that if Sirgo is still serving as a director, Sirgo shall not be entitled to such compensation in connection with cooperation under this Section 8 with claims or
litigation arising from Sirgo’s duties as a director or former officer of the Company; and provided, further, Sirgo shall not be not be entitled to reimbursement for his expenses to the extent that he has been compensated
for such expenses under the Company’s director and officer insurance policy.  
 9. No Disparagement. Neither the
Company or the Company Released Parties, on the one hand, nor Sirgo (either directly or indirectly), on the other hand, shall make any communications, whether written, electronic, oral, or otherwise, to any other person or entity, including, but not
limited to any publications and any website postings or blogs, which denigrate, defame, damage the reputation of, or otherwise cast aspersions upon each other, or their respective products, services, reputation, business and manner of doing
business.  
 10. No Modifications; Entire Agreement. This Agreement cannot be changed or terminated orally, and no
modification or waiver of any of the provisions of this Agreement will be effective unless it is in writing and signed by both parties. This Agreement sets forth the entire and fully integrated understanding between the parties, and there are no
representations, warranties, covenants or understandings, oral or otherwise, that are not expressly set out herein. The parties acknowledge that, in deciding to enter into this Agreement, they have not relied upon any statements not written in this
Agreement. 
 11. Governing Law. This Agreement shall be construed, interpreted, and governed in accordance with and by North
Carolina law. Any and all claims, controversies, and causes of action arising out of this Agreement, whether sounding in contract, tort, or statute, shall be governed by the laws of the State of North Carolina, including its statutes of limitations,
without giving effect to any North Carolina conflict-of-laws rule that would result in the application of the laws of a different jurisdiction provided, however, that claims related specifically to Sirgo’s conduct as a director of the
Company and all related corporate matters arising from his service as a director of the Company shall be construed, interpreted, and governed in accordance with and by Delaware law.  

  
 10 

 EXECUTION VERSION 

 

 12. Revocation. Sirgo may revoke this Agreement for a period of seven
(7) calendar days following the day he executes this Agreement. In order to revoke this Agreement, Sirgo must state his desire to revoke in writing and e-mail said writing to the Company’s attorney, Lawrence A. Rosenbloom, Esq., Ellenoff
Grossman & Schole LLP, at lrosenbloom@egsllp.com, on or before the seventh (7th) day after execution. Additionally, a confirmation of said revocation must be mailed, post-marked on
or before the seventh day after execution, to the Company’s attorney, Lawrence A. Rosenbloom, Esq., Ellenoff Grossman & Schole LLP, 1345 Avenue of the Americas, 11th Floor, New York, NY 10105. If the last day of the revocation period
is a Saturday, Sunday, or legal holiday, then the revocation period shall not expire until the next following day which is not a Saturday, Sunday, or legal holiday. 

13. Section 409A of the Internal Revenue Code. 

(a) Parties’ Intent. The parties intend that all payments or benefits hereunder shall either qualify for an exemption from or
comply with the applicable rules governing non-qualified deferred compensation under Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”), and the regulations thereunder (collectively, “Section
409A”) and all provisions of this Agreement shall be construed in a manner consistent with such intention. If any provision of this Agreement (or of any award of compensation, including equity compensation or benefits) would cause Sirgo to
incur any additional tax or interest under Section 409A, the Company shall, upon the specific request of Sirgo, use its reasonable business efforts to in good faith reform such provision to be exempt from, or comply with, Code
Section 409A; provided, that to the maximum extent practicable, the original intent and economic benefit to Sirgo and the Company of the applicable provision shall be maintained, and the Company shall have no obligation to make any
changes that could create any material additional economic cost or loss of material benefit to the Company. Should any provision of this Agreement or of the Employment Agreement be determined to not be in compliance with Section 409A, or should
Sirgo become liable for any excise tax, penalty or interest under Section 409A, the Company shall pay all such taxes, penalties and interest, including an additional amount to cover any additional taxes on such payments. 

(b) Release Requirement. If a payment that is deferred compensation subject to Section 409A is subject to satisfaction of a
release requirement and the period for satisfying the release requirement begins in one calendar year and ends in the following calendar year (the “Release Satisfaction Period”), then any amount becoming payable during the Release
Satisfaction Period shall not be paid until the later calendar year. 
 (c) Separation from Service. A termination of employment or
separation from service shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of any amounts or benefits that constitute nonqualified deferred compensation within the meaning of
Section 409A upon or following a termination of employment or separation from service unless such termination also constitutes a “Separation from Service” within the meaning of Section 409A and, for purposes of any such
provision of this Agreement, references to a “termination,” “termination of employment,” “separation from service” or like terms shall mean Separation from Service. 

(d) Delayed Distribution to Specified Employees. If the Company determines in accordance with Sections 409A and 416(i) of the Code and
the regulations promulgated thereunder, in the Company’s sole discretion, that a delay in benefits provided under this Agreement is necessary to comply with Code Section 409A(A)(2)(B)(i) since Sirgo is a Specified Employee thereunder, then
any post 

  
 11 

 EXECUTION VERSION 

 

 
separation payments and any continuation of benefits or reimbursement of benefit costs provided by this Agreement, and not otherwise exempt from Section 409A, shall be delayed for a period
of six (6) months following the date of Sirgo’s separation from service (the “409A Delay Period”). In such event, any post separation payments and the cost of any continuation of benefits provided under this Agreement that
would otherwise be due and payable to Sirgo during the 409A Delay Period shall not commence until, and shall be made to Sirgo in a lump sum cash amount on the first business day after the date that is six (6) months following Sirgo’s
Separation from Service and in such event the initial payment shall include a catch-up amount covering amounts that would otherwise have been paid during the six-month period following Sirgo’s Separation from Service. 

14. Section 280G of the Internal Revenue Code. 

(a) Notwithstanding any other provision of this Agreement or any other plan, arrangement or agreement to the contrary, if any of the
payments or benefits provided or to be provided by the Company or its affiliates to Sirgo or for Sirgo’s benefit pursuant to the terms of this Agreement or otherwise (“Covered Payments”) constitute parachute payments
(“Parachute Payments”) within the meaning of Section 280G of the Internal Revenue Code of 1986, as amended (the “Code”) and would, but for this Section 14, be subject to the excise tax imposed under
Section 4999 of the Code (or any successor provision thereto) or any similar tax imposed by state or local law or any interest or penalties with respect to such taxes (collectively, the “Excise Tax”), then prior to making the
Covered Payments, a calculation shall be made comparing (i) the Net Benefit (as defined below) to Sirgo of the Covered Payments after payment of the Excise Tax to (ii) the Net Benefit to Sirgo if the Covered Payments are limited to the
extent necessary to avoid being subject to the Excise Tax. Only if the amount calculated under (i) above is less than the amount under (ii) above will the Covered Payments be reduced to the minimum extent necessary to ensure that no
portion of the Covered Payments is subject to the Excise Tax (that amount, the “Reduced Amount”). “Net Benefit” shall mean the present value of the Covered Payments net of all federal, state, local, foreign income,
employment and excise taxes.  
 (b) The Covered Payments shall be reduced in a manner that maximizes Sirgo’s economic position.
In applying this principle, the reduction shall be made in a manner consistent with the requirements of Section 409A of the Code, and where two economically equivalent amounts are subject to reduction but payable at different times, such
amounts shall be reduced on a pro rata basis but not below zero. 
 (c) Any determination required under this Section 14 shall be made
in writing in good faith by an independent accounting firm selected by the Company that is reasonably acceptable to Sirgo (the “Accountants”), which shall provide detailed supporting calculations to the Company and Sirgo as
requested by the Company or Sirgo. The Company and Sirgo shall provide the Accountants with such information and documents as the Accountants may reasonably request in order to make a determination under this Section 14. For purposes of making
the calculations and determinations required by this Section 14, the Accountants may rely on reasonable, good faith assumptions and approximations concerning the application of Section 280G and Section 4999 of the Code. The
Accountants’ determinations shall be final and binding on the Company and Sirgo. The Company shall be responsible for all fees and expenses incurred by the Accountants in connection with the calculations required by this Section 14. 

(d) It is possible that after the determinations and selections made pursuant to this Section 14, Sirgo will receive Covered Payments
that are in the aggregate more than the amount provided under this Section 14 (“Overpayment”) or less than the amount provided under this Section 14 (“Underpayment”). In the event that: (A) the
Accountants determine, based upon the assertion of a deficiency by the Internal Revenue Service against either the Company or Sirgo which the Accountants 

  
 12 

 EXECUTION VERSION 

 

 
believe has a high probability of success, that an Overpayment has been made or (B) it is established pursuant to a final determination of a court or an Internal Revenue Service proceeding
that has been finally and conclusively resolved that an Overpayment has been made, then Sirgo shall pay any such Overpayment to the Company. In the event that: (A) the Accountants, based upon controlling precedent or substantial authority,
determine that an Underpayment has occurred or (B) a court of competent jurisdiction determines that an Underpayment has occurred, any such Underpayment will be paid promptly by the Company to or for the benefit of Sirgo together with interest
at the applicable federal rate (as defined in Section 7872(f)(2)(A) of the Code) from the date the amount would have otherwise been paid to Sirgo until the payment is made. 

15. Miscellaneous. 
 (a)
Should any portion, term or provision of this Agreement be declared or determined by any court to be illegal, invalid or unenforceable, the validity or the remaining portions, terms and provisions shall not be affected thereby, and the illegal,
invalid or unenforceable portion, term or provision shall be deemed not to be part of this Agreement, except that should the general release language be found to be illegal or unenforceable, Sirgo agrees to execute a binding replacement release 

(b) The parties agree that the failure of a party at any time to require performance of any provision of this Agreement shall not affect,
diminish, obviate or void in any way the party’s full right or ability to require performance of the same or any other provision of this Agreement at any time thereafter. 

(c) This Agreement shall inure to the benefit of and shall be binding upon Sirgo, his heirs, administrators, representatives, and executors,
and upon the successors and assigns of the Company. Sirgo may not (except by operation of law upon his death) assign or delegate his rights or obligations under this Agreement without the written consent of the Company. The Company’s payment
obligations to Sirgo set forth in Section 2 shall survive his death or disability prior to the Retirement Date and, in the event of his death, will be paid to his heirs and assigns as applicable. 

(d) The headings of the paragraphs of this Agreement are for convenience only and are not binding on any interpretation of this Agreement.

 (e) This Agreement may be executed in one or more counterparts, each of which will be deemed an original but all of which together will
constitute one and the same agreement. Facsimile or PDF reproductions of original signatures shall be deemed binding for the purpose of the execution of this Agreement. 

[remainder of page intentionally left blank] 

  
 13 

 EXECUTION VERSION 

 

 SIRGO ACKNOWLEDGES THAT HE HAS HAD OVER TWENTY-ONE (21) CALENDAR DAYS TO CONSIDER THIS AGREEMENT
WHICH CONTAINS A GENERAL RELEASE AND HAS BEEN ADVISED TO CONSULT WITH AN ATTORNEY PRIOR TO HIS SIGNING OF THIS AGREEMENT AND GENERAL RELEASE. 
 HAVING
ELECTED TO EXECUTE THIS AGREEMENT, TO FULFILL THE PROMISES AND TO RECEIVE THE SUMS AND BENEFITS CONTAINED HEREIN, SIRGO FREELY AND KNOWINGLY, AND AFTER DUE CONSIDERATION, ENTERS INTO THIS AGREEMENT INTENDING TO WAIVE, SETTLE AND RELEASE ALL CLAIMS
HE HAS OR MIGHT HAVE AGAINST THE COMPANY. SIMILARLY, HAVING ELECTED TO EXECUTE THIS AGREEMENT, TO FULFILL THE PROMISES AND TO RECEIVE THE BENEFITS CONTAINED HEREIN, THE COMPANY FREELY AND KNOWINGLY, AND AFTER DUE CONSIDERATION, ENTERS INTO THIS
AGREEMENT INTENDING TO WAIVE, SETTLE AND RELEASE ALL CLAIMS IT AND ITS AFFILIATES HAVE OR MIGHT HAVE AGAINST THE SIRGO RELEASED PARTIES. 

[Signature Page Follows] 

  
 14 

 IN WITNESS WHEREOF, the parties have executed this Retirement Agreement as of the dates set forth
below. 
  

			
	BIODELIVERY SCIENCES INTERNATIONAL, INC.
		
	By:	 	/s/ Frank E. O’Donnell, Jr.
		 	Name: Frank E. O’Donnell, Jr.
		 	Title: Chairman
	
	Date: August 23, 2017
	
	/s/ Mark A. Sirgo
	Mark A. Sirgo
	
	Date: August 23, 2017

 EXHIBIT A 

SUPPLEMENTAL RELEASE AGREEMENT 

This SUPPLEMENTAL RELEASE AGREEMENT (the “Supplemental Release Agreement”) is entered into this day of
            , 2018 by and between BioDelivery Sciences International, Inc., (the “Company”), and Mark A. Sirgo, his heirs, executors, administrators, successors, and
assigns (collectively referred to throughout this Agreement as “Sirgo”). The Company and Sirgo are hereinafter collectively referred to as the “Parties.” 

WHEREAS, the Parties previously entered into a Retirement Agreement, dated August
            , 2017 (the “Retirement Agreement”), detailing the terms of Sirgo’s retirement as an officer and employee of the Company (capitalized terms used herein and
not defined herein shall have the respective meanings set forth in the Retirement Agreement); 
 WHEREAS, this Supplemental Release
Agreement formed part of the Retirement Agreement, was expressly incorporated therein, and was attached as Exhibit B to the Retirement Agreement; and 

WHEREAS, pursuant to the Retirement Agreement, Sirgo and the Company agreed to execute and deliver to the other party this Supplemental
Release Agreement containing a release of claims co-extensive and substantially similar with the release set forth in Retirement Agreement, to include the period between the execution of the Retirement Agreement and the Retirement Date. 

NOW THEREFORE, for good and valuable consideration, including but not limited to the payments and benefits detailed under Section 2 of
the Retirement Agreement, the provision of which is conditioned on Sirgo’s signing, returning and not revoking this Supplemental Release Agreement, the Parties hereby agree to the following: 

1. Sirgo and the Company will maintain the terms of this Supplemental Release Agreement confidential to the extent practicable and as
permitted by law; provided, however, that (a) Sirgo may disclose the terms of this Agreement to Sirgo’s immediate family members and to Sirgo’s attorneys, accountants, financial or tax advisors, and (b) nothing in this
Section 1 is intended to prohibit Sirgo or the Company from providing truthful information to any governmental agency, arbitrator, or court, or to otherwise testify truthfully under oath, as required by law or to the extent necessary to enforce
the terms of this Agreement. 
 2. Sirgo’s Release. In consideration of the terms hereof, Sirgo, agrees to and does waive any
and all claims Sirgo may have for employment by the Company. Sirgo knowingly and voluntarily releases and forever discharges the Company and its affiliates, divisions, predecessors, insurers, successors and assigns, and their current and former
partners, employees, attorneys, officers, directors and agents thereof, both individually and in their business capacities, and their employee benefit plans and programs and their administrators and fiduciaries (collectively referred to throughout
the remainder of this Agreement as the “Company Released Parties”), of and from any and all claims, known and unknown, asserted or unasserted, which Sirgo has or may have against the Company Released Parties as of the date of execution of
this Agreement, including, but not limited to, (i) any claims, whether statutory, common law, or otherwise, arising out of the terms or conditions of his employment or partnership at the Company; (ii) any claims, whether statutory, common
law, or otherwise, arising out of the facts and circumstances of his employment and the termination of his employment at the Company; (iii) any claims for breach of contract, quantum meruit, unjust enrichment, breach of oral promise, tortious
interference with business relations, injurious falsehood, defamation, negligent or intentional infliction of emotional distress, invasion of privacy, and any other common law contract and tort claims; (iv) any claims for

  
 1 

 
unpaid or lost benefits or salary, bonus, vacation pay, severance pay, or other compensation; (v) any claims for attorneys’ fees, costs, disbursements, or other expenses; (vi) any
claims for damages or personal injury; (vii) any claims of employment discrimination, harassment or retaliation, whether based on federal, state, or local law or judicial or administrative decision; and (viii) any claims arising under the
Fair Labor Standards Act, 29 U.S.C.§ 201, et seq.; Title VII of the Civil Rights Act of 1964, 42 U.S.C. § 2000e, et seq. (as amended); the Civil Rights Act of 1866, 42 U.S.C. § 1981; the Civil Rights Act of 1991, Pub. Law
No. 102-166; the National Labor Relations Act, 29 U.S.C. § 151, et seq.; the Family and Medical Leave Act, 29 U.S.C. § 2601 et seq.; the Rehabilitation Act of 1973, 29 U.S.C. § 701, et seq.; the Age Discrimination in Employment
Act; the Older Workers Benefit Protection Act; the Worker Adjustment and Retraining Notification Act; the Americans With Disabilities Act, 42 U.S.C. § 12101, et seq.; the Employee Retirement Income Security Act of 1974, 29 U.S.C. §1001, et
seq., the Sarbanes-Oxley Act of 2002, 18 U.S.C. §1514A, et seq., the Dodd-Frank Wall Street Reform and Consumer Protection Act, claims under North Carolina or other state laws, including but not limited to the North Carolina Retaliatory
Employment Discrimination Act, the North Carolina Persons with Disabilities Protection Act, the North Carolina Equal Employment Practices Act, and/or any other federal, state or local statute, law, ordinance, regulation or order, or the common law,
or any self-regulatory organization rule or regulation. Sirgo acknowledges that he has received any and all leaves (paid or unpaid) to which he may have been entitled during his employment. The enumeration of specific rights, claims, and causes of
action being released should not be construed to limit the general scope of this Release. It is the intent of Sirgo and the Company that by this Release, Sirgo is giving up all rights, claims, and causes of actions against the Company Released
Parties which accrued prior to the effective date hereof, whether or not he is aware of them and whether or not any damage or injury has yet occurred. This release does not include either Party’s right to enforce the terms of this Agreement. In
connection with this release provision, Sirgo does not waive his right to file a charge or participate in any proceeding of any federal, state or local governmental agency, including the Equal Employment Opportunity Commission, the National Labor
Relations Board, and the Securities and Exchange Commission. To the extent permitted by law, Sirgo agrees that if such a claim is made, Sirgo shall not be entitled to recover any individual monetary relief or other individual remedies should any
administrative agency pursue any claim on his behalf. Nothing in this Supplemental Release Agreement extinguishes any claims Sirgo may have: (i) against the Company for breach of the Retirement Agreement; (ii) against any of the Company
Released Parties for any claims arising from events that occur following the Effective Date; or (iii) related to the Company’s obligation, if any, to indemnify Sirgo as an officer of the Company, including under any directors’ and
officers’ liability policy maintained by the Company. 
 3. The Company’s Release. In consideration of the mutual
agreements and covenants herein contained, by signing this Agreement, the Company knowingly and voluntarily releases and forever discharges Sirgo, his affiliates, and his attorneys and representatives (collectively referred to throughout the
remainder of this Agreement as “Sirgo Released Parties”), of and from any and all claims, known and unknown, asserted or unasserted, which the Company has or may have against Sirgo or any Sirgo Released Parties as of the date of execution
of this Agreement, including, but not limited to: (i) any claims, whether statutory, common law, or otherwise; (ii) any claims for breach of contract, breach of fiduciary duty, conversion, quantum meruit, unjust enrichment, breach of oral
promise, tortuous interference with business relations, injurious falsehood, defamation, and any other common law contract and tort claims; (iii) any claims for attorneys’ fees, costs, disbursements, or other expenses; and (vi) any
claims for damages; provided, however, that expressly excluded from such released claims are (A) claims arising out of Sirgo’s capacity as an officer or employee of the Company for fraud, criminal acts, intentional misconduct, or
actively concealed grossly negligent acts, and (B) any claims relating specifically to Sirgo’s actions or omissions as a director of the Company. The enumeration of specific rights, claims, and causes of action being released should not be
construed to limit the general scope of the foregoing release. It is the intent of Sirgo and the Company that by the foregoing release, the Company is giving up all rights, claims, and causes of actions against the Sirgo Released Parties which

  
 2 

 
accrued prior to the effective date hereof, whether or not he is aware of them and whether or not any damage or injury has yet occurred. This release does not include either Party’s right to
enforce the terms of this Agreement. Nothing in this Agreement extinguishes any claims the Company may have: (i) against Sirgo for breach of the Retirement Agreement or this Agreement; or (ii) against any of the Sirgo Released Parties for
any claims arising from events that occur following the Effective Date (as defined in the Supplemental Release Agreement). 
 4. Sirgo and
the Company acknowledge that before entering into this Agreement, each party has had the opportunity to consult with an attorney. Sirgo further acknowledges that he has entered into this Agreement of his own free will, and that no promises or
representations have been made to him by any person to induce him to enter into this Agreement other than the express terms set forth herein. Sirgo further acknowledges that he has read this Agreement and understands all of its terms, including the
waiver and release of claims set forth in Section 2 above. Sirgo further acknowledges that he has been afforded 21 days or more to consider this Agreement before signing and returning it. 

5. Sirgo and the Company must sign this Supplemental Release Agreement on the Retirement Date or within three (3) business days
thereafter. Under no circumstances is Sirgo or the Company to return the Supplemental Release Agreement to the Company’s President or sign the Supplemental Release Agreement prior to the Retirement Date. 

6. Sirgo may revoke his acceptance of this Supplemental Release Agreement for a period of seven (7) calendar days following the day he
executes this Supplemental Release Agreement. In order to revoke this Supplemental Release Agreement, Sirgo must state his desire to revoke in writing and, on or before the seventh day after execution, e-mail said writing to the Company’s
Attorney, Lawrence A. Rosenbloom, Esq., at lrosenbloom@egsllp.com. Additionally, a confirmation of said revocation must be mailed, post-marked on or before the seventh day after execution, to Lawrence A. Rosenbloom, Esq., Ellenoff
Grossman & Schole LLP, 1345 Avenue of the Americas, 11th Floor, New York, NY 10105. If the last day of the revocation period is a Saturday, Sunday, or legal holiday, then the revocation period shall not expire until the next following day
which is not a Saturday, Sunday, or legal holiday. 
 7. The “Effective Date” of this Supplemental Release Agreement shall be the
eighth (8th) business day after Sirgo’s execution hereof. The Company’s failure to execute this Supplemental Release Agreement shall not relieve the Company of its full obligations
under the Retirement Agreement, including its obligations under Section 2. 
 SIRGO ACKNOWLEDGES THAT HE HAS HAD OVER TWENTY-ONE (21) CALENDAR
DAYS TO CONSIDER THIS AGREEMENT WHICH CONTAINS A GENERAL RELEASE AND HAS BEEN ADVISED TO CONSULT WITH AN ATTORNEY PRIOR TO HIS SIGNING OF THIS AGREEMENT AND GENERAL RELEASE. 

HAVING ELECTED TO EXECUTE THIS AGREEMENT, TO FULFILL THE PROMISES AND TO RECEIVE THE SUMS AND BENEFITS CONTAINED HEREIN, SIRGO FREELY AND KNOWINGLY, AND
AFTER DUE CONSIDERATION, ENTERS INTO THIS AGREEMENT INTENDING TO WAIVE, SETTLE AND RELEASE ALL CLAIMS HE HAS OR MIGHT HAVE AGAINST THE COMPANY. SIMILARLY, HAVING ELECTED TO EXECUTE THIS AGREEMENT, TO FULFILL THE PROMISES AND TO RECEIVE THE BENEFITS
CONTAINED HEREIN, THE COMPANY FREELY AND KNOWINGLY, AND AFTER DUE CONSIDERATION, ENTERS INTO THIS AGREEMENT INTENDING TO WAIVE, SETTLE AND RELEASE ALL CLAIMS IT AND ITS AFFILIATES HAVE OR MIGHT HAVE AGAINST THE SIRGO RELEASED PARTIES. 

  
 3 

 IN WITNESS WHEREOF, the parties have executed this Supplemental Release Agreement as of the dates
set forth below. 
  

			
	BIODELIVERY SCIENCES INTERNATIONAL, INC.

 
			
		
	By: 	 	 
		 	Name:
		 	Title:

 
			
		
	Date: 	 	 
		
	 	 	 
	Mark A. Sirgo

 
			
		
	Date: 	 	 

  
 4Exhibit

Exhibit 4.13
IMPAX LABORATORIES, INC.
2001 NON-QUALIFIED EMPLOYEE STOCK PURCHASE PLAN
As amended and restated this 16th day of May, 2017
1.Purpose of Plan.
The purpose of the Impax Laboratories, Inc. 2001 Non-Qualified Employee Stock Purchase Plan, as amended and restated from time to time (the “Plan”), is to enhance employee interest in the success and progress of Impax Laboratories, Inc. (the “Company”) by encouraging employee ownership of Common Stock, $0.01 par value, of the Company (“Common Stock”). The Plan provides the opportunity to purchase Common Stock at a fifteen percent (15%) discount to the Fair Market Value (as defined below) through payroll deductions.
2.Eligible Employees.
Any employee (as determined by the Company in its sole discretion and without reference to any definition of employee under the Internal Revenue Code of 1986, as amended (the “Code”), or any other statutory or regulatory definition) of the Company or its subsidiaries designated by the Plan Committee (as defined below) for participation (except such executive officers of the Company or its subsidiaries as the Plan Committee may determine) is eligible to participate in the Plan, provided the employee:
(a)has attained the age of 21;
(b)is employed by the Company or any of its subsidiaries on the first day of each Purchase Period (as defined below);
(c)has been continuously employed by the Company or any of its subsidiaries (or any predecessor) for one calendar year preceding the effective date of participation; and
(d)has customary employment of a minimum of 20 hours per week during at least five months of the year. 
Employees eligible to participate in the Plan as defined in this Section 2 are referred to as “Eligible Employees.”
3.Election to Participate.
Participation in the Plan is voluntary. Each employee who is an Eligible Employee may participate in the Plan by completing and delivering to the Company’s payroll department an Enrollment/Withdrawal Form. The completed Enrollment/Withdrawal Form must be received by the payroll department no later than 14 days prior to the beginning of a payroll period in order to participate in the Plan for that payroll period and subsequent payroll periods. Employees who timely elect to participate in the Plan in accordance with this Section 3 are referred to herein as “Participating Employees.”
An election to participate in the Plan authorizes the Company to withhold amounts from the Participating Employee’s paycheck for the payroll periods following timely submission of the Enrollment/Withdrawal Form. A Participating Employee may at any time increase or decrease his or her payroll deduction effective with the next payroll period by timely filing a new Enrollment/Withdrawal Form. So long as the Plan remains in effect, once an employee enrolls in the Plan, he or she will automatically continue participation on the same basis, unless he or she elects to change deduction amounts, withdraws from participation in the Plan, or becomes ineligible to participate in the Plan. Changes in deduction amounts or participation in the Plan must be communicated in writing to the Company’s payroll department through timely submission of a new Enrollment/Withdrawal Form.
4.Investing in the Plan.
Except as provided in Section 23 of the Plan, Participating Employees may not invest in the Plan through lump-sum contributions.

1

5.Payroll Deductions.
Elections for payroll deductions pursuant to the Plan must be made in whole dollar amounts and specified on the Enrollment/Withdrawal Form. The minimum dollar amount for payroll deductions is $10.00 per pay period for employees that are paid weekly and $20.00 per pay period for employees that are paid bi-weekly or semimonthly.
6.Use of Funds; No Interest Paid.
All funds received by the Company under the Plan will be included in the general funds of the Company and may be used by the Company for any corporate purpose. No separate account or trust fund will be established to hold funds received under the Plan. No interest will be paid to any Participating Employee for amounts invested in the Plan.
7.Purchases of Common Stock Under the Plan.
As of each Purchase Date (as defined in Section 8 of the Plan), each Participating Employee will be deemed to have purchased, without any further action, a number of whole and fractional shares of Common Stock determined by dividing the amount of his or her payroll deductions for the preceding Purchase Period (as defined below) by eighty-five percent (85%) of the Fair Market Value of a share of Common Stock as of the Purchase Date. Fractional shares purchased for a Purchase Period will be combined with purchases for subsequent Purchase Periods to make whole shares.
Purchase Periods begin on the first day of each of the Company’s accounting months and end on the day immediately preceding the commencement date of the following Purchase Period (each, a “Purchase Period”). The Plan Committee has the power to change the commencement date or duration of a Purchase Period with respect to any future Purchase Period if the change is announced at least 14 days prior to the scheduled beginning of the Purchase Period to be affected.
8.Purchase Price.
The purchase price for each whole or fractional share of Common Stock purchased under the Plan will be eighty-five percent (85%) of the Fair Market Value of the whole or fractional share on the first trading day of the Common Stock after the end of each calendar month (as opposed to accounting month, if different) on which it is administratively practicable to execute a purchase of shares of Common Stock (the “Purchase Date”).
 “Fair Market Value” of the Common Stock as of a Purchase Date will be determined by the Plan Committee by any fair and reasonable means, including (a) if the Common Stock is listed for trading on a national securities exchange or is quoted in the over-the-counter market on the basis of last sales prices, the average of the high and low sales prices on the exchange or over-the-counter market on the Purchase Date or (b) if the Common Stock is not listed for trading on a national securities exchange or quoted in the over-the-counter market on the basis of last sales prices, but is traded in the over-the-counter market, the average of the bid and asked prices for the Common Stock at the close of business on the Purchase Date.
9.Investment Accounts.
All shares purchased under the Plan will be maintained by the Company in separate investment accounts (“Investment Accounts”) for each Participating Employee. Each Investment Account may be in the name of the Participating Employee or, if he or she so indicates on the Enrollment/Withdrawal Form, in the Participating Employee’s name jointly with a member of the Participating Employee’s family, with right of survivorship. A Participating Employee who is a resident of a jurisdiction that does not recognize a joint tenancy may have an Investment Account as tenant in common with a family member, without right of survivorship.
10.Sale or Transfer of Common Stock.
A Participating Employee may sell or transfer any Common Stock in his or her Investment Account at any time after purchase, subject to limitations, if any, imposed by applicable laws and procedures instituted by the Company. A sale may be made through 

2

the Company or outside of the Company by the Participating Employee’s own broker. Any sale or transfer is subject to any commission or other sales or transfer charges, which must be paid by the Participating Employee.

11.Limitation of Number of Shares that an Employee May Purchase.
A Participating Employee may not contribute more than $25,000 to the Plan through payroll deductions or lump-sum investments in the ESPP in one calendar year.

12.Shares Reserved for the Plan.
There will be reserved for issuance and purchase by Participating Employees under the Plan an aggregate of 2,000,000 shares of Common Stock, subject to adjustment as provided in Section 13 of the Plan. Shares subject to the Plan may be shares authorized but unissued, or shares that were once issued and subsequently reacquired by the Company.  If reserved shares are not purchased by a Participating Employee for any reason or if a right to purchase terminates as provided in the Plan, the unpurchased shares will again become available for issuance under the Plan unless the Plan has been terminated, but the unpurchased shares will not increase the aggregate number of shares reserved for purchase under the Plan.
13.Adjustment in Case of Changes Affecting the Common Stock.
If the outstanding shares of Common Stock are subdivided or split, or a stock dividend is paid thereon, the number of shares reserved under this Plan will be adjusted proportionately, and the other provisions of the Plan may be adjusted as the Board of Directors of the Company may deem necessary or equitable. If any other change affecting the Common Stock occurs, the Board of Directors may make such adjustments as it deems equitable to give proper effect to such event.
14.Right as a Stockholder.
When at least one whole share of Common Stock is deemed purchased for a Participating Employee’s Investment Account, the Participating Employee will have all of the rights or privileges of a stockholder of the Company with respect to whole or fractional shares purchased under the Plan whether or not certificates representing full shares are issued. Any cash or stock dividend or other distribution on Common Stock held in a Participating Employee’s Investment Account will be credited to the Investment Account. Proxy information will be provided for each meeting of the Company’s stockholders so that each Participating Employee may vote his or her shares in accordance with his or her instruction. If no written instructions are received on a timely basis, the voting of shares in the Participating Employee’s Investment Account will be governed by the rules and policies of the NASDAQ Stock Market and the Securities and Exchange Commission.
15.Rights Not Transferable.
The right to participate in the Plan is not transferable by a Participating Employee and is exercisable during his or her lifetime only by him or her.
16.Withdrawing from the Plan.
A Participating Employee may withdraw from the Plan at any time by properly completing and delivering an Enrollment/Withdrawal Form to the payroll department at least 14 days prior to the payroll period in which participation is to end, with the withdrawal being effective as of the end of that payroll period and thereafter. After a Participating Employee properly withdraws from the Plan, the Company will deliver to the withdrawing employee the whole shares of Common Stock credited to the withdrawing employee’s Investment Account under the Plan and will sell any fractional shares in the open market and remit the net proceeds by check. A withdrawing employee may not participate in the Plan again until the second Purchase Period after the one in which the employee withdrew. To rejoin the Plan, a new Enrollment/Withdrawal Form must be submitted.

3

17.Death, Retirement or Termination of Employment.
If a Participating Employee dies or retires or if his or her employment is terminated for any reason, the Participating Employee’s participation in the Plan will end effective immediately and the amount of the employee’s uninvested contributions will be refunded to the employee, or in the case of death to his or her estate. The Company also will deliver to the employee or his or her estate the whole shares of Common Stock credited to the employee’s Investment Account under the Plan and will sell any fractional shares in the open market and remit the net proceeds by check.
18.Administration of the Plan.
The Plan will be administered, at the Company’s expense, by the Compensation Committee of the Board of Directors or any successor committee appointed by the Board of Directors (the “Plan Committee”). Subject to the express provisions of the Plan, the Plan Committee will have authority to interpret the Plan, to prescribe, amend, and rescind rules and regulations relating to it, and to make all other determinations necessary or advisable in administering the Plan, all of which determinations will be final and binding upon all persons unless determined otherwise by the Board of Directors. The Plan Committee may delegate the day-to-day administration of the Plan and may request advice or assistance or employ such other persons as are necessary for proper administration of the Plan.
19.Amendment of the Plan.
The Board of Directors or its delegate may at any time, or from time to time, amend the Plan in any respect, except that no amendment shall be made (a) decreasing the number of shares to be reserved under the Plan (other than as provided in Section 13 of the Plan), or (b) permitting persons other than employees of the Company (as determined by the Company in its sole discretion) to participate in the Plan; provided, however, that the Plan may not be amended without the approval of the Company’s stockholders to the extent required by the rules of the securities exchange on which the Common Stock is traded or other applicable rules, regulations or laws.
20.Termination of the Plan.
The Plan and all rights of employees under the Plan will terminate: (a) on the Purchase Date that Participating Employees become entitled to purchase a number of shares greater than the number of reserved shares remaining available for purchase (and no such additional shares shall then be purchased); or (b) at any time, at the discretion of the Board of Directors or its delegate, after the completion of any Purchase Period. If the Plan terminates under clause (a), reserved shares remaining as of the termination date will be sold to Participating Employees on a pro rata basis.
21.Effective Date of Plan.
The Plan originally became effective on May 1, 2001, and this amendment and restatement is effective as of May 16, 2017.
22.Laws and Regulations.
The laws of the State of Delaware shall control all matters relating to this Plan, except to the extent superseded by the laws of the United States. The Plan and all rights and obligations of the Company and Participating Employees under the Plan are subject to all applicable federal, state, and foreign laws, rules and regulations, and to such approvals by regulatory or governmental agencies as may, in the opinion of counsel for the Company, be required. Restrictions may apply to the sale of shares of Common Stock by certain officers of the Company and those having similar responsibilities whom are subject to federal insider trading and short-swing profit rules.
23.Rules for Officers of the Company.

4

Because the federal securities laws and the Company’s Insider Trading Policy impose certain restrictions on the ability of officers of the Company and its subsidiaries to purchase Common Stock other than during certain “window periods,” these officers will be allowed to only make lump-sum investments in the Plan, and the Plan will purchase Common Stock on their behalf, as follows:
(a)Officers of the Company or its subsidiaries designated by the Plan Committee (“Designated Officers”) will be entitled to make lump-sum investments to the Plan at any time during a “window period”, as determined by the Plan Committee. An appropriate Enrollment/Withdrawal Form must be submitted to the Corporate Secretary.
(b)The Plan will purchase Common Stock for those Designated Officers making a lump-sum investment during a “window period” as soon as practicable after receipt of a check or other monetary instruments acceptable to the Company.
(c)Designated Officers may not make investments in the Plan other than as permitted in this Section 23.
(d)Designated Officers may not sell or otherwise transfer any of the Common Stock purchased on their behalf except in full compliance with applicable securities laws and the Company’s Insider Trading Policy.
(e)Except as otherwise described in this Section 23, the other provisions of the Plan will apply to purchases of Common Stock under the Plan by Designated Officers.

24.Tax Status of Plan.
The purchase of shares of Common Stock under the Plan will be made with “after-tax” dollars of Participating Employees. The amount deducted from a Participating Employee’s paycheck will have been subject previously to withholding of applicable income and employment taxes.
The Plan is not a qualified plan under the Code. Consequently, Participating Employees will realize income equal to the amount of the difference between the Fair Market Value of the Common Stock on the Purchase Date and the purchase price. Participating Employees also may realize a gain or loss on the sale of any Common Stock purchased under the Plan. Each employee is advised to consult with his or her own tax advisers prior to participation in the Plan.
The Company may make such provisions as it deems appropriate for withholding by the Company pursuant to federal or state tax laws of such amounts as the Company determines it is required to withhold in connection with the purchase or sale by a Participating Employee of any Common Stock acquired pursuant to the Plan. The Company may require a Participating Employee to satisfy any relevant tax requirements before authorizing any issuance of Common Stock to the Participating Employee.
25.ERISA.
The Plan is not subject to the Employee Retirement Income Security Act of 1974, as amended.
26.No Continued Employment.
The Plan does not confer any rights of continued employment upon any employee of the Company or any of its subsidiaries and it shall not be deemed to interfere in any way with the Company’s or its subsidiaries’ right to terminate, or otherwise modify, an employee’s employment at any time, with or without cause.
27.Effect of Plan.
The provisions of this Plan shall, in accordance with its terms, be binding upon, and inure to the benefit of, all successors of each current or former Participating Employee, including, without limitation, such Participating Employee’s estate and the executors, administrators or trustees thereof, heirs and legatees, and any receiver, trustee in bankruptcy, or representative of creditors of such Participating Employee.

5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00274-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00274-of-00352.parquet"}]]